| Display this index in Name (A-Z) order |
| Title & Synopsis | Date |
Price |
Order Form
|
| Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs 2010 This new report provides a complete review of the emerging opportunities and operating environment for inhalation and nasal spray drugs. It reviews products currently available generically and assesses the prospects for those drugs losing patent protection over the next 10 years. More>> |
Mar-2010 |
£995/
$1740/
€1245 |
|
| The World Generic Market Report 2010 This new 2 volume, 680-page edition is packed with facts, figures, analysis and statistics, that provides the most thorough analysis available on generic markets, products and companies and the issues they face. More>> |
Jan-2010 |
£595/
$1040/
€745 |
|
| Injectable Generic Drugs: Prospects & Opportunities to 2014 This market leading strategic analysis from Espicom provides the market context for injectable generic drugs, individual analysis of 55 leading therapies and evaluation of 19 companies active in the sector. Key therapy sectors include cancer, CNS, cardiovascular, anti-infectives, diabetes, growth disorders and inflammatory conditions. More>> |
Dec-2009 |
£1295/
$2265/
€1620 |
|
| Biosimilars: Beyond the first product wave With the prospect of high-profile, high-value biosimilar products on the horizon, the sector is poised to realise its full potential – but only if the US can establish a regulatory pathway. This report addresses key issues and provides insight into how the sector may develop. More>> |
Oct-2009 |
£1295/
$2265/
€1620 |
|
| Partnering in the Global Generics Industry 2009: A guide to companies Facts, statistics and insights on 170 medium-sized generic manufacturers from 40 countries. More>> |
Oct-2009 |
£595/
$1040/
€745 |
|
| Emerging Opportunities in Controlled-Release Generic Drugs This new report identifies 30 controlled-release drugs valued at US$15 billion, many of which will be losing patent protection in the medium term. More>> |
Aug-2009 |
£995/
$1740/
€1245 |
|
| The Outlook for Emerging Central American Pharmaceutical Markets Incorporating much original information, this report shines a critical light on seven markets in the region, assessing their status and potential in the current economic and market conditions: Costa Rica, El Salvador, Honduras, Guatemala, Mexico, Nicaragua and Panama. More>> |
Jan-2009 |
£795/
$1390/
€995 |
|
| All Change in the US Pharma Market? This extensive report provides a unique analysis of the likely impact of generic competition in the US pharma market. More>> |
Jun-2008 |
£995/
$1740/
€1245 |
|
| CNS Generic Drugs: Prospects and Opportunities to 2012 This important new strategic report from Espicom evaluates the CNS generic drug market and provides detailed assessment and forecast for leading products by value to 2012, patent expiry opportunities to 2015 and competitive evaluation. More>> |
Apr-2008 |
£995/
$1740/
€1245 |
|
| Opportunities and Challenges for Generic Drugs in Australia This report provides a complete assessment of the US$1.43 billion Australian generic pharmaceutical market. More>> |
Mar-2008 |
£495/
$865/
€620 |
|
| Cardiovascular Generic Drugs: Prospects and Opportunities to 2012 Focusing on the cholesterol and hypertension cardiovascular risk factors, this market leading strategic report from Espicom provides detailed assessment and forecast for leading products by value to 2012, patent expiry opportunities to 2015 and competitive evaluation. More>> |
Jan-2008 |
£995/
$1740/
€1245 |
|
| Emerging Generic Drug Markets in Europe The four EU countries analysed in this report - France, Italy, Portugal, Spain - are expected to deliver significant double digit growth over the next 5 years and present stable, regulated operating environments with excellent prospects. More>> |
Dec-2007 |
£795/
$1390/
€995 |
|
| Opportunities and Challenges for Generic Drugs in the UK The UK generic market is one of the world's largest in terms of both size and generic penetration. This report provides sets generics into the context of the pharmaceutical market as a whole, assesses the market outlook and provides forecasts to 2012. It includes an insightful review of major players in the market and detailed listing of leading products including prescription data, price comparisons and marketing authorisations. All you need to know for an informed business judgement! More>> |
Jun-2007 |
£795/
$1390/
€995 |
|
| Opportunities and Challenges for Bioequivalent Generic Drugs in Brazil This new report puts the generic market in context, providing a review of the regulatory environment, the major domestic manufacturers, market analysis and five-year market forecasts to 2012. More>> |
Apr-2007 |
£795/
$1390/
€995 |
|
| The Latin American Market for Generic Drugs Rapid growth, high unmet clinical needs and increasing regulation are changing the face of Latin American pharmaceuticals. What are the opportunities and challenges for companies and investors wanting to develop or enter this growing market? This major strategic study compares 7 key markets. More>> |
Apr-2006 |
£995/
$1740/
€1245 |